Table 1.
Definitions of treatment-resistance
| Study | Chlorpromazine dose and trial length | Number of trials necessary | Minimum length of illness | Minimum severity score | Specify symptoms | Clozapine prescription | Responsive to clozapine | Inability to live independently | Prospective confirmation |
|---|---|---|---|---|---|---|---|---|---|
| 28 | “Therapeutic doses” 6 weeks |
2 | x | ||||||
| 29 | “Adequate” 8 weeks |
2 | CGI ≥ 4 | >4 on 1+ specified PANSS item | |||||
| 17 | 400–600 4–6 weeks |
2 | 5 years | BPRS > 45 | >4 on 2+ specified BPRS items | x | |||
| 18 | 400–600 4–6 weeks |
2 | 5 years | BPRS > 45 | >4 on 2+ specified BPRS items | x | |||
| 27 | NICE algorithm | CGI < 4 | x | ||||||
| 30 | 400 mg 4 weeks |
2 | CGI > 4 | One of specified BPRS items | |||||
| 33 | 400 mg 4 weeks |
2 | CGI ≥ 4 | One of specified BPRS items | x | ||||
| 34 | “sufficient duration” | “several” | May score 5–7 | x | |||||
| 32 | “optimal clinical requirements” | 3 | Continuous for 2 years | x | |||||
| 35 | 400 mg 4 weeks |
2 | CGI ≥ 4 | One of specified BPRS items | x | ||||
| 36 | “sufficient duration” | “several” | x | ||||||
| 31 | “sufficient duration” | “several” | x | ||||||
| 37 | 1000 mg 6 weeks |
3 | BPRS > 45 CGI > 4 |
>4 on 2+ specified BPRS items | x | x | |||
| 38 | 1000 mg 8 weeks |
3 | |||||||
| 39 | 750 mg 6 weeks |
3 | Continuous for 2 years | GAS < 40 | x | ||||
| 40 | 4–6 weeks | 2 | <30% decrease in PANSS | ||||||
| 41 | Kane criteria | inclusive | inclusive | ||||||
| 42 | Therapeutic doses 6 weeks |
2 | |||||||
| 43 | 750 mg 6 weeks |
3 | 2 years | BPRS > 45 CGI > 4 |